<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04451720</url>
  </required_header>
  <id_info>
    <org_study_id>M19-135</org_study_id>
    <nct_id>NCT04451720</nct_id>
  </id_info>
  <brief_title>Study of Subcutaneous Risankizumab Injection to Assess Change in Palmoplantar Pustulosis Area and Severity Index [PPPASI] in Adult Japanese Participants With Palmoplantar Pustulosis</brief_title>
  <official_title>A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Risankizumab in Adult Japanese Subjects With Moderate to Severe Palmoplantar Pustulosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Palmoplantar pustulosis is a chronic inflammatory skin disease that causes repeated on and
      off symptoms like erythema (reddening, irritation), vesicle (swelling, cyst), pustules,
      scale, and crusts in palms and soles. This study evaluates how well risankizumab works
      compared to placebo (no medicine) to treat palmoplantar pustulosis. Study will assess change
      in Palmoplantar Pustulosis Area and Severity Index [PPPASI].

      Risankizumab is an investigational drug being developed for the treatment of palmoplantar
      pustulosis. This study is &quot;double-blinded&quot;, which means that neither the trial participants
      nor the study doctors will know who will be given study drug and who will receive placebo (no
      medicine). Participants are randomly put into 1 of 2 groups, called treatment arms to receive
      risankizumab or placebo in period A. In period B, each group receives both risankizumab and
      placebo at different time intervals. Around 116 adult participants with palmoplantar
      pustulosis will be enrolled in approximately 39 sites across Japan.

      Participants will receive subcutaneous (SC) injections of risankizumab or placebo at Week 0
      and Week 4 (Period A). Beginning Week 16 (Period B), both the groups will receive
      risankizumab and placebo at different intervals. Total treatment duration is 56 weeks.

      There may be a higher burden for participants in this trial compared to their standard of
      care. Participants will attend regular visits during the course of the study at a hospital or
      clinic. The effect of the treatment will be checked by medical assessments, blood tests,
      checking for side effects and completing questionnaires.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 7, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 27, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Palmoplantar Pustulosis Area and Severity Index (PPPASI) Total Score</measure>
    <time_frame>Baseline (Week 0) through Week 16</time_frame>
    <description>The Palmoplantar Pustulosis Area and Severity Index (PPPASI) assesses the severity of palmoplantar pustulosis lesions and their response to therapy. In the PPPASI system, the palms and soles are divided into 4 regions: the right palm, left palm, right sole, left sole which account for 20%, 20%, 30%, and 30%, respectively, of the total surface area of the palms and soles. Each of these areas are assessed separately for erythema, pustules/vesicle and desquamation/scale, which are each rated on a scale of 0 to 4. The PPPASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving at least 50% Improvement in PPPASI (PPPASI-50)</measure>
    <time_frame>Baseline (Week 0) through Week 16</time_frame>
    <description>The Palmoplantar Pustulosis Area and Severity Index (PPPASI) assesses the severity of palmoplantar pustulosis lesions and their response to therapy. In the PPPASI system, the palms and soles are divided into 4 regions: the right palm, left palm, right sole, left sole which account for 20%, 20%, 30%, and 30%, respectively, of the total surface area of the palms and soles. Each of these areas are assessed separately for erythema, pustules/vesicle and desquamation/scale, which are each rated on a scale of 0 to 4. The PPPASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving at least 75% Improvement in PPPASI (PPPASI-75)</measure>
    <time_frame>Baseline (Week 0) through Week 16</time_frame>
    <description>The Palmoplantar Pustulosis Area and Severity Index (PPPASI) assesses the severity of palmoplantar pustulosis lesions and their response to therapy. In the PPPASI system, the palms and soles are divided into 4 regions: the right palm, left palm, right sole, left sole which account for 20%, 20%, 30%, and 30%, respectively, of the total surface area of the palms and soles. Each of these areas are assessed separately for erythema, pustules/vesicle and desquamation/scale, which are each rated on a scale of 0 to 4. The PPPASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Palmoplantar Pustulosis (PPP)</condition>
  <arm_group>
    <arm_group_label>Risankizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Period A, participants will receive risankizumab dose A at Weeks 0 and 4. In Period B, participants will receive risankizumab dose A at Weeks 16, 28, 40 and 52, and also placebo at Weeks 20, 32, 44 and 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Period A, participants will receive placebo at Weeks 0 and 4. In period B, participants will receive risankizumab dose A at Weeks 16, 20,32,44 and 56. and also placebo at Weeks 28,40 and 52.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risankizumab</intervention_name>
    <description>Subcutaneous (SC) injection</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Risankizumab</arm_group_label>
    <other_name>SKYRIZI</other_name>
    <other_name>ABBV-066</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous (SC) injection</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Risankizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stable moderate to severe Palmoplantar Pustulosis (PPP) with a Palmoplantar Pustulosis
             Area and Severity Index (PPPASI) total score of &gt;= 12 at the Screening and Baseline
             Visits.

          -  Moderate or severe pustules/vesicles on at least one palm or sole (&gt;= 2 PPPASI
             severity score) at the Screening and Baseline Visits.

          -  Experienced inadequate response (or intolerant) to treatment with topical
             corticosteroids and/or vitamin D3 derivative preparations and/or phototherapy and/or
             systemic etretinate.

        Exclusion Criteria:

          -  History of active skin disease other than PPP which could interfere with the
             assessment of PPP.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>847.283.8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chukyo Hospital /ID# 218894</name>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi</state>
        <zip>457-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Toho University Sakura Medical Center /ID# 220858</name>
      <address>
        <city>Sakura-shi</city>
        <state>Chiba</state>
        <zip>285-8741</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fukushima Medical University Hospital /ID# 221639</name>
      <address>
        <city>Fukushima-shi</city>
        <state>Fukushima</state>
        <zip>960-1295</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gifu University Hospital /ID# 219109</name>
      <address>
        <city>Gifu-shi</city>
        <state>Gifu</state>
        <zip>501-1194</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ogaki Municipal Hospital /ID# 220801</name>
      <address>
        <city>Ogaki-shi</city>
        <state>Gifu</state>
        <zip>503-8502</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Takagi Dermatological Clinic /ID# 220896</name>
      <address>
        <city>Obihiro-shi</city>
        <state>Hokkaido</state>
        <zip>080-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bito Dermatology Clinic /ID# 222750</name>
      <address>
        <city>Kobe-shi</city>
        <state>Hyogo</state>
        <zip>651-0095</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ibaraki Prefectural Central Hospital /ID# 222712</name>
      <address>
        <city>Kasama</city>
        <state>Ibaraki</state>
        <zip>309-1793</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mito Kyodo General Hospital /ID# 220799</name>
      <address>
        <city>Mito-shi</city>
        <state>Ibaraki</state>
        <zip>310-0015</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Sagamihara National Hospital /ID# 219082</name>
      <address>
        <city>Sagamihara-shi</city>
        <state>Kanagawa</state>
        <zip>252-0315</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yokohama City University Hospital /ID# 220860</name>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa</state>
        <zip>2360004</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Kyoto Prefectural University of Medicine /ID# 221376</name>
      <address>
        <city>Kyoto-shi</city>
        <state>Kyoto</state>
        <zip>6028566</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mie University Hospital /ID# 221570</name>
      <address>
        <city>Tsu-shi</city>
        <state>Mie</state>
        <zip>514-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital /ID# 219017</name>
      <address>
        <city>Sendai-shi</city>
        <state>Miyagi</state>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shinshu University Hospital /ID# 221343</name>
      <address>
        <city>Matsumoto-shi</city>
        <state>Nagano</state>
        <zip>〒390-8621</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nagasaki University Hospital /ID# 221141</name>
      <address>
        <city>Nagasaki-shi</city>
        <state>Nagasaki</state>
        <zip>852-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nagaoka Red Cross Hospital /ID# 221375</name>
      <address>
        <city>Nagaoka-shi</city>
        <state>Niigata</state>
        <zip>940-2108</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Isonokami dermatological clinic /ID# 219023</name>
      <address>
        <city>Daito-shi</city>
        <state>Osaka</state>
        <zip>5740046</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kindai University Hospital /ID# 219022</name>
      <address>
        <city>Osaka-sayama-shi</city>
        <state>Osaka</state>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka City University Hospital /ID# 222012</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kume Clinic /ID# 220869</name>
      <address>
        <city>Sakai-shi</city>
        <state>Osaka</state>
        <zip>5938324</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dokkyo Medical University Saitama Medical Center /ID# 222526</name>
      <address>
        <city>Koshigaya-shi</city>
        <state>Saitama</state>
        <zip>343-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shizuoka Saiseikai Genaral Hospital /ID# 222427</name>
      <address>
        <city>Shizuoka-shi</city>
        <state>Shizuoka</state>
        <zip>422-8021</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dokkyo Medical University Hospital /ID# 221210</name>
      <address>
        <city>Shimotsuga-gun</city>
        <state>Tochigi</state>
        <zip>321-0293</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St.Luke's International Hospital /ID# 219019</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Teikyo University Hospital /ID# 221089</name>
      <address>
        <city>Itabashi-ku</city>
        <state>Tokyo</state>
        <zip>173-8605</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University Hospital /ID# 218893</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seibo Hospital /ID# 221691</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>161-8521</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokai University Hospital /ID# 220945</name>
      <address>
        <city>Isehara</city>
        <zip>259-1143</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kansai Medical Univ Kori Hosp /ID# 223096</name>
      <address>
        <city>Neyagawa</city>
        <zip>572-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meiwa Hospital /ID# 221633</name>
      <address>
        <city>Nishinomiya, Hyogo</city>
        <zip>663-8186</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Takamatsu Red Cross Hospital /ID# 221344</name>
      <address>
        <city>Takamatsu</city>
        <zip>760-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Jikei University Hospital /ID# 218822</name>
      <address>
        <city>Tokyo</city>
        <zip>105-8461</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ehime University Hospital /ID# 221260</name>
      <address>
        <city>Toon</city>
        <zip>791-0204</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fujita Health University Hosp /ID# 221285</name>
      <address>
        <city>Toyoake</city>
        <zip>470-1192</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://www.rxabbvie.com/</url>
    <description>This clinical study may be evaluating a usage that is not currently FDA approved. Please see US Prescribing Information for approved uses.</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 29, 2020</study_first_submitted>
  <study_first_submitted_qc>June 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2020</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Palmoplantar Pustulosis (PPP)</keyword>
  <keyword>Risankizumab</keyword>
  <keyword>SKYRIZI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

